Schizophrenia Research
Volume 118, Issue 1 , Pages 34-40 , May 2010

Executive function in schizophrenia: Influence of substance use disorder history

  • Roberto Rodriguez-Jimenez

      Affiliations

    • Department of Psychiatry, Hospital Universitario 12 de Octubre, Madrid, Spain
    • Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain
    • Corresponding Author InformationCorresponding author. Psychiatry Department, Hospital Universitario 12 de Octubre, Av. Cordoba s/n, 28041, Madrid, Spain. Tel.: +34 91 390 80 22; fax: +34 91 390 85 38.
    • ,
  • Alexandra Bagney

      Affiliations

    • Department of Psychiatry, Hospital Universitario 12 de Octubre, Madrid, Spain
    • Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain
    • ,
  • Isabel Martinez-Gras

      Affiliations

    • Department of Psychiatry, Hospital Universitario 12 de Octubre, Madrid, Spain
    • Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain
    • ,
  • Guillermo Ponce

      Affiliations

    • Department of Psychiatry, Hospital Universitario 12 de Octubre, Madrid, Spain
    • Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain
    • ,
  • Eva Maria Sanchez-Morla

      Affiliations

    • Department of Psychiatry, Hospital General Universitario, Guadalajara, Spain
    • ,
  • Maria Aragües

      Affiliations

    • Department of Psychiatry, Hospital Universitario 12 de Octubre, Madrid, Spain
    • Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain
    • ,
  • Gabriel Rubio

      Affiliations

    • Department of Psychiatry, Hospital Universitario 12 de Octubre, Madrid, Spain
    • Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain
    • ,
  • Miguel Angel Jimenez-Arriero

      Affiliations

    • Department of Psychiatry, Hospital Universitario 12 de Octubre, Madrid, Spain
    • Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain
    • ,
  • Jose Luis Santos

      Affiliations

    • Department of Psychiatry, Hospital Virgen de La Luz, Cuenca, Spain
    • ,
  • Tomas Palomo

      Affiliations

    • Department of Psychiatry, Hospital Universitario 12 de Octubre, Madrid, Spain
    • Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain
    • ,
  • PARG

      Affiliations

    • Psychosis and Addictions Research Group (PARG): L. Agüera, S. Alfonso, M. Aragües, A. Bagney, J. Ballester, J.J. Belloso, E. Bermudez, M. Caballero, J. Camarasa, P. Cano, J. Diez, J. Hoenicka, P. Holgado, M.A. Jimenez-Arriero, R. Jurado, I. Martinez-Gras, M.J. Muñiz, M. Navio, T. Palomo, G. Ponce, J. Ramos, R. Rodriguez-Jimenez, J. Rodriguez-Torresano, G. Rubio, I. Rubio, E.M. Sanchez-Morla, J.L. Santos, S. Solera, S. Vega, C. Villanueva, M.J. del Yerro.

Received 6 May 2009 ,Revised 27 July 2009 ,Accepted 24 September 2009.

References 

  1. Addington J, Addington D. Substance abuse and cognitive functioning in schizophrenia. J. Psychiatry Neurosci. 1997;2:99–104
  2. Addington J, Addington D, Maticka-Tyndale E. Cognitive functioning and positive and negative symptoms in schizophrenia. Schizophr. Res. 1991;5:123–134
  3. Addington J, Brooks BL, Addington D. Cognitive functioning in first episode psychosis: initial presentation. Schizophr. Res. 2003;44:47–56
  4. Albus M, Hubmann W, Ehrenberg Ch, Forcht U, Mohr F, Sobizack N, et al. Neuropsychological impairment in first-episode and chronic schizophrenic patients. Eur. Arch. Psychiatry Clin. Neurosci. 1996;246:249–255
  5. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders. 4th ed.. Washington, DC: American Psychiatric Association; 1994;
  6. Ascher-Svanum H, Zhu B, Faries D, Lacro JP, Dolder CR. A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophrenia. J. Clin. Psychiatry. 2006;67:1114–1123
  7. Berman I, Viegner B, Merson A, Allan E, Pappas D, Green AI. Differential relationships between positive and negative symptoms and neuropsychological deficits in schizophrenia. Schizophr. Res. 1997;25:1–10
  8. Bilder RM, Goldman RS, Robinson D, Reiter G, Bell L, Bates JA, et al. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am. J. Psychiatry. 2000;157:549–559
  9. Bleuler E. Dementia Praecox or the Group of Schizophrenias. New York: International Universities Press; 1950;
  10. Bowie CR, Harvey PD. Cognition in schizophrenia: impairments, determinants, and functional importance. Psychiatr. Clin. North Am. 2005;28(613–633):626
  11. Bowie CR, Leung WW, Reichenberg A, McClure MM, Patterson TL, Heaton RK, et al. Predicting schizophrenia patients' real-world behavior with specific neuropsychological and functional capacity measures. Biol. Psychiatry. 2008;63:505–511
  12. Breier A, Schreiber JL, Dyer J, Pickar D. National Institute of Mental Health longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome. Arch. Gen. Psychiatry. 1991;48:239–246
  13. Buchanan RW, Strauss ME, Kirkpatrick B, Holstein C, Breier A, Carpenter WT. Neuropsychological impairments in deficit vs nondeficit forms of schizophrenia. Arch. Gen. Psychiatry. 1994;51:804–811
  14. Bühler B, Hambrecht M, Löffler W, an der Heiden W, Häfner H. Precipitation and determination of the onset and course of schizophrenia by substance abuse—a retrospective and prospective study of 232 population-based first illness episodes. Schizophr. Res. 2002;54:243–251
  15. Cantor-Graae E, Nordstrom LG, McNeil TF. Substance abuse in schizophrenia: a review of the literature and a study of correlates in Sweden. Schizophr. Res. 2001;48:69–82
  16. Capleton RA. Cognitive function in schizophrenia: association with negative and positive symptoms. Psychol. Rep. 1996;78:123–128
  17. Carey KB, Carey MP, Simons JS. Correlates of substance use disorder among psychiatric outpatients: focus on cognition, social role functioning, and psychiatric status. J. Nerv. Ment. Dis. 2003;191:300–308
  18. Censits DM, Ragland JD, Gur RC, Gur RE. Neuropsychological evidence supporting a neurodevelopmental model of schizophrenia: a longitudinal study. Schizophr. Res. 1997;24:289–298
  19. Chen EY, Lam LC, Chen RY, Nguyen DG. Negative symptoms, neurological signs and neuropsychological impairments in 204 Hong Kong Chinese patients with schizophrenia. Br. J. Psychiatry. 1996;168:227–233
  20. Cleghorn JM, Kaplan RD, Szechtman B, Szechtman H, Brown HG, Franco S. Substance abuse and schizophrenia: effect on symptoms but not on neurocognitive function. J. Clin. Psychiatry. 1991;52:26–30
  21. Craig TJ, Bromet EJ, Fennig S, Tanenberg-Karant M, Lavelle J, Galambos N. Is there an association between duration of untreated psychosis and 24-month clinical outcome in a first-admission series?. Am. J. Psychiatry. 2000;157:60–66
  22. Cuesta MJ, Peralta V, Caro F, De Leon J. Schizophrenic syndrome and Wisconsin Card Sorting Test card dimensions. Psychiatry Res. 1995;58:45–51
  23. Dixon L. Dual diagnosis of substance abuse and schizophrenia: prevalence and impact on outcomes. Schizophr. Res. 1999;35:S93–S100
  24. Dixon L, Haas G, Weiden PJ, Sweeney J, Frances AJ. Drug abuse in schizophrenic patients: clinical correlates and reasons for use. Am. J. Psychiatry. 1991;148:224–230
  25. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders—Patient Edition (SCID-I/P, Version 2.0). Biometrics Research Department, New York State Psychiatric Institute, New York. 1995;
  26. Friedman JI, Harvey PD, Coleman T, Moriarty PJ, Bowie C, Parrella M, et al. Six-year follow-up study of cognitive and functional status across the lifespan in schizophrenia: a comparison with Alzheimer's disease and normal aging. Am. J. Psychiatry. 2001;158:1441–1448
  27. Friedman JI, Harvey PD, McGurk SR, White L, Parrella M, Raykov T, et al. Correlates of change in functional status of institutionalized geriatric schizophrenic patients: focus on medical comorbidity. Am. J. Psychiatry. 2002;159:1388–1394
  28. Gold S, Arndt S, Nopoulos P, O'Leary DS, Andreasen NC. Longitudinal study of cognitive function in first-episode and recent-onset schizophrenia. Am. J. Psychiatry. 1999;156:1342–1348
  29. Golden CJ. Stroop Color and Word Test: A Manual for Clinical and Experimental Uses. Chicago, IL: Stoelting Co.; 1978;
  30. Good KP, Rabinowitz J, Whitehorn D, Harvey PD, DeSmedt G, Kopala LC. The relationship of neuropsychological test performance with the PANSS in antipsychotic naive, first-episode psychosis patients. Schizophr. Res. 2004;68:11–19
  31. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am. J. Psychiatry. 1996;153:321–330
  32. Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”?. Schizophr. Bull. 2000;26:119–136
  33. Green MF, Nuechterlein KH, Kern RS, Baade LE, Fenton WS, Gold JM, et al. Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study. Am. J. Psychiatry. 2008;165:221–228
  34. Harvey PD, Parrella M, White L, Mohs RC, Davidson M, Davis KL. Convergence of cognitive and adaptive decline in late-life schizophrenia. Schizophr. Res. 1999;35:77–84
  35. Harvey PD, Silverman JM, Mohs RC, Parrella M, White L, Powchik P, et al. Cognitive decline in late-life schizophrenia: a longitudinal study of geriatric chronically hospitalized patients. Biol. Psychiatry. 1999;45:32–40
  36. Harvey PD, Serper MR, White L, Parrella MJ, McGurk SR, Moriarty PJ, et al. The convergence of neuropsychological testing and clinical ratings of cognitive impairment in patients with schizophrenia. Compr. Psychiatry. 2001;42:306–313
  37. Heaton RK. Wisconsin Card Sorting Test Manual. Odessa, FL: Psychological Assessment Resources; 1981;
  38. Heaton RK, Gladsjo JA, Palmer BW, Kuck J, Marcotte TD, Jeste DV. Stability and course of neuropsychological deficits in schizophrenia. Arch. Gen. Psychiatry. 2001;58:24–32
  39. Heinrichs RW. The primacy of cognition in schizophrenia. Am. Psychol. 2005;60:229–242
  40. Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology. 1998;12:426–445
  41. Herman M. Neurocognitive functioning and quality of life among dually diagnosed and non-substance abusing schizophrenia inpatients. Int. J. Ment. Health Nurs. 2004;13:282–291
  42. Hill SK, Schuepbach D, Herberner ES, Keshavan MS, Sweeney JA. Pretreatment and longitudinal studies of neuropsychological deficits in antipsychotic-naive patients with schizophrenia. Schizophr. Res. 2004;68:49–63
  43. Himelhoch S, Taylor SF, Goldman RS, Tandon R. Frontal lobe tasks, antipsychotic medication, and schizophrenia syndromes. Biol. Psychiatry. 1996;39:227–229
  44. Ho BC, Andreasen NC, Flaum M, Nopoulos P, Miller D. Untreated initial psychosis: its relation to quality of life and symptom remission in first-episode schizophrenia. Am. J. Psychiatry. 2000;157:808–815
  45. Ho BC, Alicata D, Ward J, Moser DJ, O'Leary DS, Arndt S, et al. Untreated initial psychosis: relation to cognitive deficits and brain morphology in first-episode schizophrenia. Am. J. Psychiatry. 2003;160:142–148
  46. Hofer A, Niedermayer B, Kemmler G, Rettenbacher MA, Trebo E, Widschwendter CG, et al. Cognitive impairment in schizophrenia: clinical ratings are not a suitable alternative to neuropsychological testing. Schizophr. Res. 2007;92:126–131
  47. Hoff AL, Sakuma M, Wieneke M, Horon R, Kushner M, DeLisi LE. Longitudinal neuropsychological follow-up study of patients with first episode schizophrenia. Am. J. Psychiatry. 1999;156:1336–1341
  48. Hoff AL, Sakuma M, Razi K, Heydebrand G, Csernansky JG, DeLisi LE. Lack of association between duration of untreated illness and severity of cognitive and structural brain deficits at the first episode of schizophrenia. Am. J. Psychiatry. 2000;157:1824–1828
  49. Hoff AL, Svetina C, Shields G, Stewart J, DeLisi LE. Ten year longitudinal study of neuropsychological functioning subsequent to a first episode of schizophrenia. Schizophr. Res. 2005;78:27–34
  50. Janssen B, Gaebel W, Haerter M, Komaharadi F, Lindel B, Weinmann S. Evaluation of factors influencing medication compliance in inpatient treatment of psychotic disorders. Psychopharmacology (Berl). 2006;187:229–236
  51. Joyal CC, Hallé P, Lapierre D, Hodgins S. Drug abuse and/or dependence and better neuropsychological performance in patients with schizophrenia. Schizophr. Res. 2003;63:297–299
  52. Kavanagh DJ, McGrath J, Saunders JB. Substance misuse in patients with schizophrenia: epidemiology and management. Drugs. 2002;62:743–755
  53. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987;13:261–276
  54. Keefe RS, Fenton WS. How should DSM-V criteria for schizophrenia include cognitive impairment?. Schizophr. Bull. 2007;33:912–920
  55. Kraepelin E. Dementia Praecox and Paraphrenia. Edinburgh, Scotland: E. & S. Livingstone; 1919;
  56. Kurtz MM. Neurocognitive impairment across the lifespan in schizophrenia: an update. Schizophr. Res. 2005;74:15–26
  57. Liddle PF, Morris DL. Schizophrenic syndromes and frontal lobe performance. Br. J. Psychiatry. 1991;158:340–345
  58. Lieh-Mak F, Lee PW. Cognitive deficit measures in schizophrenia: factor structure and clinical correlates. Am. J. Psychiatry. 1997;154:S39–S46
  59. Lundqvist T. Cognitive consequences of cannabis use: comparison with abuse of stimulants and heroin with regard to attention, memory and executive functions. Pharmacol. Biochem. Behav. 2005;81:319–330
  60. Margolese HC, Malchy L, Negrete JC, Tempier R, Gill K. Drug and alcohol use among patients with schizophrenia and related psychoses: levels and consequences. Schizophr. Res. 2004;67:157–166
  61. Maynard C, Cox GB. Psychiatric hospitalization of persons with dual diagnoses: estimates from two national surveys. Psychiatr. Serv. 1998;49:1615–1617
  62. McCleery A, Addington J, Addington D. Substance misuse and cognitive functioning in early psychosis: a 2year follow-up. Schizophr. Res. 2006;88:187–191
  63. Melle I, Larsen TK, Haahr U, Friis S, Johannesen JO, Opjordsmoen S, et al. Prevention of negative symptom psychopathologies in first-episode schizophrenia: two-year effects of reducing the duration of untreated psychosis. Arch. Gen. Psychiatry. 2008;65:634–640
  64. Mohamed S, Paulsen JS, O‘Leary D, Arndt S, Andreasen N. Generalized cognitive deficits in schizophrenia. Arch. Gen. Psychiatry. 1999;56:749–754
  65. Mueser KT, Yarnold PR, Rosenberg SD, Swett C, Miles KM, Hill D. Substance use disorder in hospitalized severely mentally ill psychiatric patients: prevalence, correlates and subgroups. Schizophr. Bull. 2000;26:179–192
  66. Nieuwenstein MR, Aleman A, de Haan EH. Relationship between symptom dimensions and neurocognitive functioning in schizophrenia: a meta-analysis of WCST and CPT studies. Wisconsin Card Sorting Test. Continuous Performance Test. J. Psychiat. Res. 2001;35:119–125
  67. Nixon SJ, Hallford GH, Tivis RD. Neurocognitive function in alcoholic, schizophrenic, and dually diagnosed patients. Psychiatry Res. 1996;64:35–45
  68. Nuechterlein KH, Barch DM, Gold JM, Goldberg TE, Green MF, Heaton RK. Identification of separable cognitive factors in schizophrenia. Schizophr. Res. 2004;72:29–39
  69. Owen RR, Fischer EP, Booth BM, Cuffel BJ. Medication noncompliance and substance abuse among patients with schizophrenia. Psychiatr. Serv. 1996;47:853–858
  70. Pencer A, Addington J. Substance use and cognition in early psychosis. J. Psychiatry Neurosci. 2003;8:48–54
  71. Perkins DO, Gu H, Weiden PJ, McEvoy JP, Hamer RM, Lieberman JA. Comparison of Atypicals in First Episode study group. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. J. Clin. Psychiatry. 2008;69:106–113
  72. Perry W, Braff DL. A multimethod approach to assessing perseverations in schizophrenic patients. Schizophr. Res. 1998;33:69–77
  73. Potvin S, Briand C, Prouteau A, Bouchard RH, Lipp O, Lalonde P, et al. CANTAB explicit memory is less impaired in addicted schizophrenia patients. Brain Cogn. 2005;59:38–42
  74. Potvin S, Joyal CC, Pelletier J, Stip E. Contradictory cognitive capacities among substance-abusing patients with schizophrenia: a meta-analysis. Schizophr. Res. 2008;100:242–251
  75. Ragland JD, Censits DM, Gur RC, Glahn DC, Gallacher F, Gur RE. Assessing declarative memory in schizophrenia using Wisconsin Card Sorting Test stimuli: the paired associate recognition test. Psychiatry Res. 1996;60:135–145
  76. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, et al. Comorbidity of mental disorders with alcohol and other drug abuse. JAMA. 1990;264:2511–2518
  77. Reitan RM, Wolfson D. The Halstead–Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation. second ed.. South Tucson, Arizona: Neuropsychology Press; 1993;
  78. Rodriguez-Jimenez R, Aragües M, Jimenez-Arriero MA, Ponce G, Martinez I, Hoenicka J, et al. Psychopathology and Wisconsin Card Sorting Test performance in male schizophrenic patients: influence of dual diagnosis. Psychopathology. 2008;41:58–64
  79. Rogers RD, Robbins TW. Investigating the neurocognitive deficits associated with chronic drug misuse. Curr. Opin. Neurobiol. 2001;11:250–257
  80. Rosse RB, Schwartz BL, Kim SY, Deutsch SI. Correlation between antisaccade and Wisconsin Card Sorting Task performance in schizophrenia. Am. J. Psychiatr. 1993;150:333–335
  81. Rund BR. A review of longitudinal studies of cognitive functions in schizophrenia patients. Schizophr. Bull. 1998;24:425–435
  82. Rund BR, Melle I, Friis S, Larsen TK, Midbøe LJ, Opjordsmoen S, et al. Neurocognitive dysfunction in first-episode psychosis: correlates with symptoms, premorbid adjustment, and duration of untreated psychosis. Am. J. Psychiatry. 2004;161:466–472
  83. Saykin AJ, Shtasel DL, Gur RE, Kester DB, Mozley LH, Stafiniak P, et al. Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch. Gen. Psychiatry. 1994;51:124–131
  84. Scheurich A. Neuropsychological functioning and alcohol dependence. Curr. Opin. Psychiatry. 2005;18:319–323
  85. Serper MR, Bergman A, Copersino ML, Chou JCY, Richarme D, Cancro R. Learning and memory impairment in cocaine dependent and comorbid schizophrenic patients. Psychiatry Res. 2000;93:21–32
  86. Serper MR, Copersino ML, Richarme D, Vadhan N, Cancro R. Neurocognitive functioning in recently abstinent, cocaine abusing schizophrenic patients. J. Subst. Abuse. 2000;11:205–213
  87. Sevy S, Kay SR, Opler L, van Praag HM. Significance of cocaine history in schizophrenia. J. Nerv. Ment. Dis. 1990;178:642–648
  88. Sevy S, Robinson DG, Holloway S, Alvir JM, Woerner MG, Bilder R, et al. Correlates of substance misuse in patients with first-episode schizophrenia and schizoaffective disorder. Acta Psychiatr. Scand. 2001;104:367–374
  89. Spiga S, Lintas A, Diana M. Addiction and cognitive functions. Ann. N. Y. Acad. Sci. 2008;1139:299–306
  90. Stirling J, Lewis S, Hopkins R, White C. Cannabis use prior to first onset psychosis predicts spared neurocognition at 10-year follow-up. Schizophr. Res. 2005;75:135–137
  91. Talamo A, Centorrino F, Tondo L, Dimitri A, Hennen J, Baldessarini RJ. Comorbid substance-use in schizophrenia: relation to positive and negative symptoms. Schizophr. Res. 2006;86:251–255
  92. Thoma P, Wiebel B, Daum I. Response inhibition and cognitive flexibility in schizophrenia with and without comorbid substance use disorder. Schizophr. Res. 2007;92:168–180
  93. Toda M, Abi-Dargham A. Dopamine hypothesis of schizophrenia: making sense of it all. Curr. Psychiatry Rep. 2007;9:329–336
  94. Torrey EF. Studies of individuals with schizophrenia never treated with antipsychotic medication: a review. Schizophr. Res. 2002;58:101–115
  95. Verdejo-García AJ, López-Torrecillas F, Aguilar de Arcos F, Pérez-García M. Differential effects of MDMA, cocaine, and cannabis use severity on distinctive components of the executive functions in polysubstance users: a multiple regression analysis. Addict. Behav. 2005;30:89–101
  96. Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophr. Bull. 1991;17:325–351
  97. Yücel M, Lubman DI, Solowijm N, Brewer WJ. Understanding drug addiction: a neuropsychological perspective. Aust. N. Z. J. Psychiatry. 2007;41:957–968

PII: S0920-9964(09)00469-1

doi: 10.1016/j.schres.2009.09.025

Schizophrenia Research
Volume 118, Issue 1 , Pages 34-40 , May 2010

Article Tools

* Image Usage & Resolution